The effect of pravastatin combined with fenofibrate in treatment of mixed hyperlipidemia
Ruan Weijie
Abstract
Ruan Weijie
Abstract
Objective To investigate the clinical effect of pravastatin and fenofibrate in treatment of mixed hyperlipidemia.Methods All of 211 cases of mixed hyperlipidemia patients were randomly divided into combined group,pravastatin group and fenofibrate group,in which low-dose combination group fenofibrate combination therapy with pravastatin,pravastatin group and fenofibrate group were used to separate treatment of pravastatin and fenofibrate.Clinical lipid levels,efficacy and adverse reactions compared in three groups.Results The total effective rate of combined group was significantly higher than pravastatin group and fenofibrate group(P 0.05).Three groups had no significant difference in adverse events(P 0.05).Conclusion Pravastatin combined with fenofibrate in treatment of mixed hyperlipidemia has a good clinical efficacy,fewer adverse reactions.So it is worthy of clinical use.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Objective To investigate the clinical effect of pravastatin and fenofibrate in treatment of mixed hyperlipidemia.Methods All of 211 cases of mixed hyperlipidemia patients were randomly divided into combined group,pravastatin group and fenofibrate group,in which low-dose combination group fenofibrate combination therapy with pravastatin,pravastatin group and fenofibrate group were used to separate treatment of pravastatin and fenofibrate.Clinical lipid levels,efficacy and adverse reactions compared in three groups.Results The total effective rate of combined group was significantly higher than pravastatin group and fenofibrate group(P 0.05).Three groups had no significant difference in adverse events(P 0.05).Conclusion Pravastatin combined with fenofibrate in treatment of mixed hyperlipidemia has a good clinical efficacy,fewer adverse reactions.So it is worthy of clinical use.
Key concepts: Pravastatin, Fenofibrate, Medicine, Hyperlipidemia, Adverse effect, Internal medicine, Clinical efficacy, Gastroenterology